Jazz secures FDA approval for Ziihera in advanced HER2+ GEA
The decision follows results from the Phase III HERIZON-GEA-01 trial, which showed significant improvements with Ziihera-based treatments.
Drug Development
McKesson to acquire Precision Medicine Group for $2.25bn
Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Gossamer Bio announces $250m in funding to advance seralutinib
WellSpan and Johns Hopkins renew partnership for advanced cancer care access
Charles River and MVC to develop enterovirus vaccine
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy
